Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer

Robert D. Loberg; Jeffery R. Fielhauer; Brian A. Pienta; Scott Dresden; Patty Christmas; Linda M. Kalikin; Karin B. Olson; Kenneth J. Pienta

doi:10.1016/j.urology.2003.10.026

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer

Robert D. Loberg, Jeffery R. Fielhauer, Brian A. Pienta, Scott Dresden, Patty Christmas, Linda M. Kalikin, Karin B. Olson, Kenneth J. Pienta

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

The relation between tumor kinetics and disease progression in patients with hormone-refractory prostate cancer (HRPC) has not been well described. Biochemical recurrence of prostate cancer is characterized by detectable prostate-specific antigen (PSA) levels after treatment and occurs in approximately 30% of patients after therapy for apparent localized disease. An increase in PSA almost always occurs before clinical evidence of disease. The ability to identify early biochemical failure in patients to assess disease aggressiveness and guide changes in treatment needs to be examined. We examined serial PSA data from 249 patients with metastatic disease to assess PSA doubling time (PSADT) in hormone-naive prostate cancer (HNPC) and HRPC states. In a subset of patients, the relation of PSADT to Gleason score and survival was studied. PSADT decreased from 37.5 ± 4.5 weeks to 15.6 ± 1.6 weeks (mean ± SEM) in patients with HNPC versus HRPC. In this small study, PSADT did not correlate with Gleason score, survival from start of hormonal treatment, length of time receiving hormone therapy, or survival in the HRPC state. The decrease in PSADT with disease state may help provide insight into understanding the biology of late-stage disease.

Original language	English (US)
Pages (from-to)	128-133
Number of pages	6
Journal	Urology
Volume	62
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/j.urology.2003.10.026
State	Published - 2003
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.urology.2003.10.026

Cite this

@article{0df39397293f4e81bdc5c04d12b29e99,

title = "Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer",

abstract = "The relation between tumor kinetics and disease progression in patients with hormone-refractory prostate cancer (HRPC) has not been well described. Biochemical recurrence of prostate cancer is characterized by detectable prostate-specific antigen (PSA) levels after treatment and occurs in approximately 30% of patients after therapy for apparent localized disease. An increase in PSA almost always occurs before clinical evidence of disease. The ability to identify early biochemical failure in patients to assess disease aggressiveness and guide changes in treatment needs to be examined. We examined serial PSA data from 249 patients with metastatic disease to assess PSA doubling time (PSADT) in hormone-naive prostate cancer (HNPC) and HRPC states. In a subset of patients, the relation of PSADT to Gleason score and survival was studied. PSADT decreased from 37.5 ± 4.5 weeks to 15.6 ± 1.6 weeks (mean ± SEM) in patients with HNPC versus HRPC. In this small study, PSADT did not correlate with Gleason score, survival from start of hormonal treatment, length of time receiving hormone therapy, or survival in the HRPC state. The decrease in PSADT with disease state may help provide insight into understanding the biology of late-stage disease.",

author = "Loberg, {Robert D.} and Fielhauer, {Jeffery R.} and Pienta, {Brian A.} and Scott Dresden and Patty Christmas and Kalikin, {Linda M.} and Olson, {Karin B.} and Pienta, {Kenneth J.}",

note = "Funding Information: This work was supported in part by a grant from the National Institutes of Health/National Cancer Institute (Specialized Program in Research Excellence [SPORE] in Prostate Cancer) ",

year = "2003",

doi = "10.1016/j.urology.2003.10.026",

language = "English (US)",

volume = "62",

pages = "128--133",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer

AU - Loberg, Robert D.

AU - Fielhauer, Jeffery R.

AU - Pienta, Brian A.

AU - Dresden, Scott

AU - Christmas, Patty

AU - Kalikin, Linda M.

AU - Olson, Karin B.

AU - Pienta, Kenneth J.

N1 - Funding Information: This work was supported in part by a grant from the National Institutes of Health/National Cancer Institute (Specialized Program in Research Excellence [SPORE] in Prostate Cancer)

PY - 2003

Y1 - 2003

N2 - The relation between tumor kinetics and disease progression in patients with hormone-refractory prostate cancer (HRPC) has not been well described. Biochemical recurrence of prostate cancer is characterized by detectable prostate-specific antigen (PSA) levels after treatment and occurs in approximately 30% of patients after therapy for apparent localized disease. An increase in PSA almost always occurs before clinical evidence of disease. The ability to identify early biochemical failure in patients to assess disease aggressiveness and guide changes in treatment needs to be examined. We examined serial PSA data from 249 patients with metastatic disease to assess PSA doubling time (PSADT) in hormone-naive prostate cancer (HNPC) and HRPC states. In a subset of patients, the relation of PSADT to Gleason score and survival was studied. PSADT decreased from 37.5 ± 4.5 weeks to 15.6 ± 1.6 weeks (mean ± SEM) in patients with HNPC versus HRPC. In this small study, PSADT did not correlate with Gleason score, survival from start of hormonal treatment, length of time receiving hormone therapy, or survival in the HRPC state. The decrease in PSADT with disease state may help provide insight into understanding the biology of late-stage disease.

AB - The relation between tumor kinetics and disease progression in patients with hormone-refractory prostate cancer (HRPC) has not been well described. Biochemical recurrence of prostate cancer is characterized by detectable prostate-specific antigen (PSA) levels after treatment and occurs in approximately 30% of patients after therapy for apparent localized disease. An increase in PSA almost always occurs before clinical evidence of disease. The ability to identify early biochemical failure in patients to assess disease aggressiveness and guide changes in treatment needs to be examined. We examined serial PSA data from 249 patients with metastatic disease to assess PSA doubling time (PSADT) in hormone-naive prostate cancer (HNPC) and HRPC states. In a subset of patients, the relation of PSADT to Gleason score and survival was studied. PSADT decreased from 37.5 ± 4.5 weeks to 15.6 ± 1.6 weeks (mean ± SEM) in patients with HNPC versus HRPC. In this small study, PSADT did not correlate with Gleason score, survival from start of hormonal treatment, length of time receiving hormone therapy, or survival in the HRPC state. The decrease in PSADT with disease state may help provide insight into understanding the biology of late-stage disease.

UR - http://www.scopus.com/inward/record.url?scp=1842829885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842829885&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2003.10.026

DO - 10.1016/j.urology.2003.10.026

M3 - Article

C2 - 14747050

AN - SCOPUS:1842829885

SN - 0090-4295

VL - 62

SP - 128

EP - 133

JO - Urology

JF - Urology

IS - SUPPL. 1

ER -

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this